Perturbations of the AKT signaling pathway in human cancer - PubMed (original) (raw)
Review
. 2005 Nov 14;24(50):7455-64.
doi: 10.1038/sj.onc.1209085.
Affiliations
- PMID: 16288292
- DOI: 10.1038/sj.onc.1209085
Review
Perturbations of the AKT signaling pathway in human cancer
Deborah A Altomare et al. Oncogene. 2005.
Abstract
AKT/PKB (protein kinase B) kinases mediate signaling pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases regulate diverse cellular processes including cell proliferation and survival, cell size and response to nutrient availability, tissue invasion and angiogenesis. Many oncoproteins and tumor suppressors implicated in cell signaling/metabolic regulation converge within the AKT signal transduction pathway in an equilibrium that is altered in many human cancers by activating and inactivating mechanisms, respectively, targeting these inter-related proteins. We review a burgeoning literature implicating aberrant AKT signaling in many sporadic human cancers as well as in several dominantly inherited cancer syndromes known as phakomatoses. The latter include disorders caused by germline mutations of certain tumor suppressor genes, that is, PTEN, TSC2/TSC1, LKB1, NF1, and VHL, encoding proteins that intersect with the AKT pathway. We also review various pathogenic mechanisms contributing to activation of the AKT pathway in human malignancy as well as current pharmacologic strategies to target therapeutically components of this pathway.
Similar articles
- Activation of AKT kinases in cancer: implications for therapeutic targeting.
Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Bellacosa A, et al. Adv Cancer Res. 2005;94:29-86. doi: 10.1016/S0065-230X(05)94002-5. Adv Cancer Res. 2005. PMID: 16095999 Review. - AKT signaling in normal and malignant cells.
Testa JR, Tsichlis PN. Testa JR, et al. Oncogene. 2005 Nov 14;24(50):7391-3. doi: 10.1038/sj.onc.1209100. Oncogene. 2005. PMID: 16288285 - Diverse mechanisms of AKT pathway activation in human malignancy.
Cheung M, Testa JR. Cheung M, et al. Curr Cancer Drug Targets. 2013 Mar;13(3):234-44. doi: 10.2174/1568009611313030002. Curr Cancer Drug Targets. 2013. PMID: 23297823 Free PMC article. Review. - Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ. Zhang H, et al. J Clin Invest. 2003 Oct;112(8):1223-33. doi: 10.1172/JCI17222. J Clin Invest. 2003. PMID: 14561707 Free PMC article. - PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ. Zhang H, et al. J Clin Invest. 2007 Mar;117(3):730-8. doi: 10.1172/JCI28984. Epub 2007 Feb 8. J Clin Invest. 2007. PMID: 17290308 Free PMC article.
Cited by
- Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors.
Poustforoosh A. Poustforoosh A. Mol Biotechnol. 2024 Oct 27. doi: 10.1007/s12033-024-01307-2. Online ahead of print. Mol Biotechnol. 2024. PMID: 39463205 - Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.
Chang Y, Wang X, Yang J, Tien JC, Mannan R, Cruz G, Zhang Y, Vo JN, Magnuson B, Mahapatra S, Cho H, Dhanasekaran SM, Wang C, Wang Z, Zhou L, Zhou K, Zhou Y, Zhang P, Huang W, Xiao L, Liu WR, Hamadeh R, Su F, Wang R, Miner SJ, Cao X, Cheng Y, Mehra R, Ding K, Chinnaiyan AM. Chang Y, et al. Cell Rep Med. 2024 Oct 15;5(10):101752. doi: 10.1016/j.xcrm.2024.101752. Epub 2024 Sep 30. Cell Rep Med. 2024. PMID: 39353441 Free PMC article. - Screening of mtr-miR156a from exosomes of dairy cow blood to milk and its regulatory effect on milk protein synthesis in BMECs.
Shaojin L, Jingying J, Baobao L, Yahui L, Hongjuan D, Ma Y, Xiaoyan C. Shaojin L, et al. BMC Genomics. 2024 Sep 19;25(1):882. doi: 10.1186/s12864-024-10761-w. BMC Genomics. 2024. PMID: 39300336 Free PMC article. - PSAT1 Promotes Metastasis via p-AKT/SP1/ITGA2 Axis in Estrogen Receptor-Negative Breast Cancer Cell.
Zhang X, Wang S, Li W, Wang J, Gong Y, Chen Q, Cao S, Pang D, Gao S. Zhang X, et al. Biomolecules. 2024 Aug 12;14(8):990. doi: 10.3390/biom14080990. Biomolecules. 2024. PMID: 39199378 Free PMC article. - mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer.
Li W, Huang M, Wu Z, Zhang Y, Cai Y, Su J, Xia J, Yang F, Xiao D, Yang W, Xu Y, Liu Z. Li W, et al. Adv Sci (Weinh). 2024 Aug;11(32):e2309988. doi: 10.1002/advs.202309988. Epub 2024 Jun 21. Adv Sci (Weinh). 2024. PMID: 39189475 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA06927/CA/NCI NIH HHS/United States
- R01 CA077429/CA/NCI NIH HHS/United States
- P50 CA083638/CA/NCI NIH HHS/United States
- CA77429/CA/NCI NIH HHS/United States
- P30 CA006927/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous